Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Net Income (2024 - 2025)

Kura Oncology (KURA) has disclosed Net Income for 2 consecutive years, with -$81.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income fell 370.95% to -$81.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$278.4 million, a 61.92% decrease, with the full-year FY2025 number at -$278.7 million, down 60.17% from a year prior.
  • Net Income was -$81.0 million for Q4 2025 at Kura Oncology, down from -$74.1 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$17.2 million in Q4 2024 to a low of -$81.0 million in Q4 2025.